Rituximab for High-Risk, Mature B-Cell Non-Hodgkin's Lymphoma in Children.

ABSTRACT:

Background

Rituximab added to chemotherapy prolongs survival among adults with B-cell cancer. Data on its efficacy and safety in children with high-grade, mature B-cell non-Hodgkin's lymphoma are limited.

Methods

We conducted an open-label, international, randomized, phase 3 trial involving patients younger than 18 years of age with high-risk, mature B-cell non-Hodgkin's lymphoma (stage III with an elevated lactate dehydrogenase level or stage IV) or acute leukemia to compare the addition of six doses of rituximab to standard lymphomes malins B (LMB) chemotherapy with standard LMB chemotherapy alone. The primary end point was event-free survival. Overall survival and toxic effects were also assessed.

Results

Analyses were based on 328 patients who underwent randomizat

SUBMITTER: Minard-Colin V 

PROVIDER: S-EPMC7720281 | biostudies-literature | 2020 Jun

REPOSITORIES: biostudies-literature